Zura Bio Ltd

JATT Acquisition Corp (Nasdaq: JATT), sponsored by JATT Ventures, completed its initial public offering in 2021 targeting opportunities in technology-enabled healthcare businesses. In January 2023, the company announced a definitive business combination with Zura Bio Ltd, a clinical-stage biopharmaceutical company concentrated on inflammation and autoimmune disease therapeutics. The transaction has since closed, with Zura Bio emerging as a publicly listed entity through the de-SPAC process, marking the conclusion of JATT Acquisition Corp's lifecycle as a blank-check vehicle. The deal represented a notable move into clinical-stage biotech within the broader healthcare sector. Visit SpacDesk and sign up for full deal data, filing history, and company analytics on JATT and Zura Bio.

SPAC Counterparty (1)